Roth Mkm reissued their buy rating on shares of Forian (NASDAQ:FORA – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. Roth Mkm currently has a $5.00 target price on the stock.
Forian Price Performance
NASDAQ FORA opened at $2.00 on Thursday. The company has a fifty day moving average of $2.13 and a two-hundred day moving average of $2.43. The company has a market capitalization of $62.22 million, a PE ratio of -22.22 and a beta of 1.09. Forian has a 1 year low of $1.99 and a 1 year high of $4.15.
Forian (NASDAQ:FORA – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.06). The company had revenue of $4.78 million during the quarter, compared to analysts’ expectations of $5.26 million. During the same quarter in the previous year, the company earned ($0.03) EPS.
Hedge Funds Weigh In On Forian
Forian Company Profile
Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.
Further Reading
- Five stocks we like better than Forian
- How to Plot Fibonacci Price Inflection Levels
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Trading Stocks: RSI and Why it’s Useful
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Most Volatile Stocks, What Investors Need to Know
- Time to Load Up on Home Builders?
Receive News & Ratings for Forian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forian and related companies with MarketBeat.com's FREE daily email newsletter.